Company Description
OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States.
The company’s technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners’ drug development efforts.
Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates.
The company’s OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities.
OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 106 |
| CEO | Matthew W. Foehr |
Contact Details
Address: 5980 Horton Street, Suite 600 Emeryville, California 94608 United States | |
| Phone | 510-250-7800 |
| Website | omniab.com |
Stock Details
| Ticker Symbol | OABI |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001846253 |
| CUSIP Number | 68218J103 |
| ISIN Number | US68218J1034 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Matthew W. Foehr | President, Chief Executive Officer and Director |
| Kurt A. Gustafson | Executive Vice President of Finance and Chief Financial Officer |
| Charles S. Berkman J.D. | Chief Legal Officer and Secretary |
| Cia McCaffrey | Vice President of People and Talent |
| Dr. Bill Harriman Ph.D. | Senior Vice President of Antibody Discovery |
| Marie-Cecile van de Lavoir D.V.M., Ph.D. | Senior Vice President of Technical Operations and Genetics |
| Dr. Christel Iffland Ph.D. | Senior Vice President of Antibody Technologies |
| Dr. Douglas S. Krafte Ph.D. | Senior Vice President of Ion Channels/Transporters and Icagen Ion Channel Technology Site Head |
| Donna Ventura CPA | Senior Vice President of Corporate Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Jul 1, 2024 | 8-K | Current Report |
| Jun 21, 2024 | 8-K | Current Report |
| May 9, 2024 | 10-Q | Quarterly Report |
| May 9, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |
| Apr 8, 2024 | 144 | Filing |
| Apr 8, 2024 | 144 | Filing |